Your browser doesn't support javascript.
loading
The Challenges of Measuring Socioeconomic Inequality in Pharmacoepidemiology Studies.
Prener, Christopher; Schley, Katharina; Miles, Amanda; Willis, Sarah.
Affiliation
  • Prener C; Pfizer, Inc., New York, NY.
  • Schley K; Pfizer Pharma GmbH, Berlin, Germany.
  • Miles A; Pfizer, Inc., New York, NY.
  • Willis S; Pfizer, Inc., Cambridge, MA.
Am J Epidemiol ; 2024 Sep 17.
Article in En | MEDLINE | ID: mdl-39289170
ABSTRACT
Social conditions like socioeconomic status (SES) are critical sources of health disparities. In pharmacoepidemiology research, our ability to measure SES in retrospective, real world clinical data remains challenged by a lack of patient-reported data. Some broadly accepted concepts can be measured at the individual level, such as income, poverty, and education. Community-level measures such as the Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) also exist. After reflecting on these existing measures and discussing the challenges for leveraging them with real world data, we offer three recommendations that we believe could improve the ability of pharmacoepidemiologists to better measure and interrogate the effect of SES in their own research. These recommendations include a greater collection of patient-reported metrics, reduced reliance on ZIP Codes and ZIP Code Tabulation Areas for creating community-level measures of deprivation, and the inclusion of GIS and demography specialists within pharmacoepidemiology teams.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Epidemiol Year: 2024 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Epidemiol Year: 2024 Document type: Article Country of publication: United States